uniQure (Nasdaq: QURE) has been a public company since 2014.

We thank our investors for their support as we advance our gene therapy pipeline toward commercialization.
Contact us at any time.

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease modifying therapies to patients with severe disorders.

We are leveraging our modular and validated technology platform to rapidly advance a focused pipeline of gene therapies.

Stock Quote

Recent News

Upcoming Webcast:
May 23, 2017
UBS Global Healthcare Conference
Tuesday, May 23, 2017

3:00 p.m. EDT/ 9:00 p.m. CET
Click here to view webcast

Webcast Archive: 

May 12, 2017
Investor and Analyst Breakfast & Webcast 
Friday, May 12, 2017
07:00 a.m. EDT/ 13:00 CET

Click here to view webcast

 Upcoming Events:

May 22-24, 2017
UBS Global Healthcare Conference, New York City 

May 23-24, 2017
American Biomanufacturing Summit, San Diego, CA